Clinical Trial: Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex

Study Status: Terminated
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Treatment of Moderate to Severe Patients With Pemphigus With the Monoclonal Anti CD20 Antibody Rituximab at a Protocol of 1000mgX2 and Assessment of Their Immune Status Vi

Brief Summary: The purpose of this study is to determine whether Rituximab, in the same doses as used in rheumatoid arthritis patients, will benefit pemphigus patients. It also tests immune function via the Cylex assay in pemphigus patients before and after treatment with RItuximab.

Detailed Summary:
Sponsor: Rabin Medical Center

Current Primary Outcome: Complete or partial remission off treatment (based on the consensus statement for pemphigus) [ Time Frame: 6 months after treatment ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Rabin Medical Center

Dates:
Date Received: April 17, 2011
Date Started: January 2010
Date Completion: June 2012
Last Updated: April 29, 2011
Last Verified: March 2011